Patients with suspected eosinophilic gastrointestinal disease (EGID) in the stomach or duodenum had an increased number of mucosal mast cells with or without mucosal eosinophilia.
The researchers discovered significant differences and substantial heterogeneity in risk for GC among API subgroups. Substantial differences in all-cause survival among API subgroups were also observed.
Recommendations were developed and graded in accordance with the ESMO Clinical Practice Guidelines and subjected to an anonymous peer-review process.
Reductions in gastric cancer mortality seen with H. pylori treatment, vitamin, garlic supplementation.
Patients receiving gastric acid inhibitors have an increase in prescriptions of anti-allergic drugs.
Type 2 diabetes was linked to an increased risk for gastric cancer (adjusted hazard ratio, 1.73). Stratified statistical analysis demonstrated a significantly higher risk for gastric cardia cancer (adjusted hazard ratio, 3.40) and a significantly increased risk in those with suboptimal glycemic control (adjusted hazard ratio, 1.68).
The FDA has granted Breakthrough Therapy designation to teplizumab (PRV-031; Provention Bio), for the prevention or delay of clinical T1D in those at risk of developing the disease.
A case report suggests that endoscopic techniques may have utility in the diagnosis of the gastric involvement that can occur in follicular lymphoma.